The burden of influenza in the United States can vary from year to year depending on which viruses are circulating, how many people receive an influenza vaccination, and how effective the vaccination is in that particular year. During the 2023-2024 flu season, around 28,000 people lost their lives to the disease. Although most people recover from influenza without needing medical care, the disease can be deadly among young children, the elderly, and those with weakened immune systems or chronic illnesses. Deaths due to influenza Even though most people recover from influenza without medical care, influenza and pneumonia can be deadly, especially for older people and those with certain preexisting conditions. Influenza is a common cause of pneumonia and although most cases of influenza do not develop into pneumonia, those that do are often more severe and more deadly. Deaths due to influenza are most common among the elderly, with a mortality rate of around 32 per 100,000 population during the 2023-2024 flu season. In comparison, the mortality rate for those aged 50 to 64 years was 9.1 per 100,000 population. Flu vaccinations The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Nevertheless, every year a large share of the population in the United States still fails to get vaccinated against influenza. For example, in the 2022-2023 flu season, only 35 percent of those aged 18 to 49 years received a flu vaccination. Unsurprisingly, children and the elderly are the most likely to get vaccinated. It is estimated that during the 2022-2023 flu season, vaccinations prevented over 929 thousand influenza cases among children aged 6 months to 4 years.

The graph illustrates the number of flu-related deaths in the United States for each flu season from 2010-2011 to 2023-2024*. The x-axis represents the flu seasons, labeled from '10-11 to '23*-24*, while the y-axis shows the annual number of flu deaths. Throughout this period, flu deaths vary significantly, ranging from a low of 4,900 in the 2021-2022* season to a high of 51,000 in both the 2014-2015 and 2017-2018 seasons. Other notable figures include 36,000 deaths in 2010-2011, 42,000 in 2012-2013, and a recent increase to 28,000 in the 2023*-2024* season. The data exhibits considerable fluctuations with no consistent upward or downward trend, highlighting the variability in flu mortality rates over the years. This information is presented in a line graph format, effectively showcasing the yearly changes and peaks in flu-related deaths across the United States.

*Data for the 2021-2022 and 2022-2023 seasons are estimated.

During the 2023-2024 flu season in the United States, an estimated 27,965 people died from influenza. The vast majority of deaths due to influenza occur among the elderly, with those aged 65 years and older accounting for 19,038 deaths during the 2023-2024 flu season. During this time, the mortality rate from influenza among those aged 65 years and older was around 32 per 100,000 population, compared to a mortality rate of two per 100,000 population among those aged 18 to 49 years. Influenza deaths Although most people recover from influenza without the need of medical care, influenza and pneumonia are still major causes of death in the United States. Influenza is a common cause of pneumonia and cases in which influenza develops into pneumonia tend to be more severe and more deadly. However, the impact of influenza varies from year to year depending on which viruses are circulating. For example, during the 2017-2018 flu season around 52,000 people died due to influenza, whereas in 2023-2024 total deaths amounted to 28,000. Preventing death The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Each year, flu vaccinations prevent thousands of influenza cases, hospitalizations and deaths. It was estimated that during the 2022-2023 flu season, vaccinations prevented the deaths of around 2,479 people aged 65 years and older.

Influenza, also called the flu, is one of the most infectious diseases worldwide. Its symptoms range from mild to severe, and include sore throat, cough, runny nose, fever, headache, and muscle pain, but can also cause severe illness and death among high-risk populations such as the elderly and children. During the 2023-2024 flu season, there were 40 million cases of influenza in the United States. Influenza deaths Although influenza does not require medical attention for most people, it can be deadly, and causes thousands of deaths every year. The impact of influenza varies from year to year. The number of influenza deaths during the 2023-2024 flu season was 27,965. The vast majority of deaths attributed to influenza during the 2023-2024 flu season occurred among those aged 65 years and older. Vaccination An annual influenza vaccination remains the most effective way of preventing influenza. During the 2022-2023 flu season, influenza vaccinations prevented an estimated 2,479 deaths among U.S. adults aged 65 years and older. Although, flu vaccinations are accessible and cheap, a large share of the United States population still fails to get vaccinated every year. In 2022-2023, only 35 percent of those aged 18 to 49 years received a flu vaccination, much lower compared to children and the elderly.

Australia Influenza Mortality jumped by 8% in 2019, from a year earlier.

This statistic shows the estimated number of people who died worldwide during influenza pandemics. During the Spanish flu from 1918 to 1919 around ********** people were estimated to have died. More recently, between ******* and ******* people died from the swine flu or H1N1 pandemic in 2009.

Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.

Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.

WHO: Influenza A (H1N1): Number of Deaths: New Zealand data was reported at 3.000 Person in 06 Jul 2009. This records an increase from the previous number of 0.000 Person for 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: New Zealand data is updated daily, averaging 0.000 Person from Apr 2009 (Median) to 06 Jul 2009, with 74 observations. The data reached an all-time high of 3.000 Person in 06 Jul 2009 and a record low of 0.000 Person in 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: New Zealand data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Heath Organization: Influenza A (H1N1): By Countries.

Global Influenza Mortality Share by Country (Units (Male Deaths)), 2023 Discover more data with ReportLinker!

Global Influenza Mortality by Country, 2023 Discover more data with ReportLinker!

WHO: Influenza A (H1N1): Number of Deaths: India data was reported at 0.000 Person in 06 Jul 2009. This stayed constant from the previous number of 0.000 Person for 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: India data is updated daily, averaging 0.000 Person from Apr 2009 (Median) to 06 Jul 2009, with 74 observations. The data reached an all-time high of 0.000 Person in 06 Jul 2009 and a record low of 0.000 Person in 06 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: India data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Heath Organization: Influenza A (H1N1): By Countries.

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretabilty. We also formatted the data into a standard data format.

Each Project Tycho dataset contains case counts for a specific condition (e.g. measles) and for a specific country (e.g. The United States). Case counts are reported per time interval. In addition to case counts, datsets include information about these counts (attributes), such as the location, age group, subpopulation, diagnostic certainty, place of aquisition, and the source from which we extracted case counts. One dataset can include many series of case count time intervals, such as "US measles cases as reported by CDC", or "US measles cases reported by WHO", or "US measles cases that originated abroad", etc.

Depending on the intended use of a dataset, we recommend a few data processing steps before analysis:

• Analyze missing data: Project Tycho datasets do not inlcude time intervals for which no case count was reported (for many datasets, time series of case counts are incomplete, due to incompleteness of source documents) and users will need to add time intervals for which no count value is available. Project Tycho datasets do include time intervals for which a case count value of zero was reported.
• Separate cumulative from non-cumulative time interval series. Case count time series in Project Tycho datasets can be "cumulative" or "fixed-intervals". Cumulative case count time series consist of overlapping case count intervals starting on the same date, but ending on different dates. For example, each interval in a cumulative count time series can start on January 1st, but end on January 7th, 14th, 21st, etc. It is common practice among public health agencies to report cases for cumulative time intervals. Case count series with fixed time intervals consist of mutually exxclusive time intervals that all start and end on different dates and all have identical length (day, week, month, year). Given the different nature of these two types of case count data, we indicated this with an attribute for each count value, named "PartOfCumulativeCountSeries".

BackgroundWe assessed the severity of the 2009 influenza pandemic by comparing pandemic mortality to seasonal influenza mortality. However, reported pandemic deaths were laboratory-confirmed – and thus an underestimation – whereas seasonal influenza mortality is often more inclusively estimated. For a valid comparison, our study used the same statistical methodology and data types to estimate pandemic and seasonal influenza mortality. Methods and FindingsWe used data on all-cause mortality (1999–2010, 100% coverage, 16.5 million Dutch population) and influenza-like-illness (ILI) incidence (0.8% coverage). Data was aggregated by week and age category. Using generalized estimating equation regression models, we attributed mortality to influenza by associating mortality with ILI-incidence, while adjusting for annual shifts in association. We also adjusted for respiratory syncytial virus, hot/cold weather, other seasonal factors and autocorrelation. For the 2009 pandemic season, we estimated 612 (range 266–958) influenza-attributed deaths; for seasonal influenza 1,956 (range 0–3,990). 15,845 years-of-life-lost were estimated for the pandemic; for an average seasonal epidemic 17,908. For 0–4 yrs of age the number of influenza-attributed deaths during the pandemic were higher than in any seasonal epidemic; 77 deaths (range 61–93) compared to 16 deaths (range 0–45). The ≥75 yrs of age showed a far below average number of deaths. Using pneumonia/influenza and respiratory/cardiovascular instead of all-cause deaths consistently resulted in relatively low total pandemic mortality, combined with high impact in the youngest age category. ConclusionThe pandemic had an overall moderate impact on mortality compared to 10 preceding seasonal epidemics, with higher mortality in young children and low mortality in the elderly. This resulted in a total number of pandemic deaths far below the average for seasonal influenza, and a total number of years-of-life-lost somewhat below average. Comparing pandemic and seasonal influenza mortality as in our study will help assessing the worldwide impact of the 2009 pandemic.

WHO: Influenza A (H1N1): Number of Deaths: Australia data was reported at 10.000 Person in 06 Jul 2009. This records an increase from the previous number of 9.000 Person for 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Australia data is updated daily, averaging 0.000 Person from Apr 2009 (Median) to 06 Jul 2009, with 74 observations. The data reached an all-time high of 10.000 Person in 06 Jul 2009 and a record low of 0.000 Person in 21 Jun 2009. WHO: Influenza A (H1N1): Number of Deaths: Australia data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Heath Organization: Influenza A (H1N1): By Countries.

BackgroundAssessing the mortality impact of the 2009 influenza A H1N1 virus (H1N1pdm09) is essential for optimizing public health responses to future pandemics. The World Health Organization reported 18,631 laboratory-confirmed pandemic deaths, but the total pandemic mortality burden was substantially higher. We estimated the 2009 pandemic mortality burden through statistical modeling of mortality data from multiple countries.Methods and FindingsWe obtained weekly virology and underlying cause-of-death mortality time series for 2005–2009 for 20 countries covering ∼35% of the world population. We applied a multivariate linear regression model to estimate pandemic respiratory mortality in each collaborating country. We then used these results plus ten country indicators in a multiple imputation model to project the mortality burden in all world countries. Between 123,000 and 203,000 pandemic respiratory deaths were estimated globally for the last 9 mo of 2009. The majority (62%–85%) were attributed to persons under 65 y of age. We observed a striking regional heterogeneity, with almost 20-fold higher mortality in some countries in the Americas than in Europe. The model attributed 148,000–249,000 respiratory deaths to influenza in an average pre-pandemic season, with only 19% in persons

WHO: Influenza A (H1N1): Number of Deaths: Japan data was reported at 0.000 Person in 06 Jul 2009. This stayed constant from the previous number of 0.000 Person for 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Japan data is updated daily, averaging 0.000 Person from Apr 2009 (Median) to 06 Jul 2009, with 74 observations. The data reached an all-time high of 0.000 Person in 06 Jul 2009 and a record low of 0.000 Person in 06 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Japan data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Heath Organization: Influenza A (H1N1): By Countries.

According to Cognitive Market Research, the Global H1N1 (swine flu) Vaccination Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

Based on Vaccine Type, the intramuscular segment will dominate the global H1N1 (swine flu) Vaccination market in the year 2023. Based on vaccine type, the market is divided into intramuscular, intranasal, and intradermal
Based on Market Type, the public segment dominated the global H1N1 (swine flu) Vaccination market. Based on Market Type, the global H1N1 (swine flu) Vaccination market is segmented into public and private
The North American region accounted for the highest market share in the Global H1N1 (swine flu) Vaccination Market. 
Over the course of the projection period, Asia pacific is expected to increase at the fastest rate.

CURRENT SCENARIO OF THE H1N1 (SWINE FLU) VACCINATION MARKET

Key factors driving the growth of the H1N1 (swine flu) Vaccination Market

Increased incidence of disease and episodes of pandemic worldwide from H1N1 infection to drive the market growth over the forecast period

The H1N1 virus is contagious and can spread widely through small droplets of saliva from coughs or sneezes of the infected person. H1N1 virus causes damage to the respiratory system including the nose, lungs, and throat. The H1N1 virus is a Ribonucleic acid (RNA) virus belonging to the Orthomyxoviridae family. In the year 2009, a strain of swine flu called "H1N1" infected many people around the world.

According to the World Health Organization (WHO), annually about 3 to 5 million cases of severe illness and about 2,90,000 to 6,50,000 respiratory deaths are due to seasonal influenza. (Source; https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)#:~:text=There%20are%20around%20a%20billion,infections%20are%20in%20developing%20countries.)

In industrialised nations, those over 65 account for the majority of influenza-related mortality. Illnesses caused by seasonal influenza can vary in severity and sometimes result in death. Therefore, during the projected period, these elements are propelling market growth. Due to waning immunisations, the transmissible disease's prevalence is increasing daily. The main causes of impaired digesting power are the prevalence of smoking and bad eating habits.

As a result of the body's diminished ability to fight off illnesses, a number of communicable diseases are becoming more prevalent. The World Health Organisation proclaimed the H1N1 pandemic in 2009–10 after it killed over 284,000 people. Moreover, in a recent survey of 41% of households in the capital city of India more than 2-3% of cases were found positive.

Rising public health initiatives to Accelerate the Market Growth 

Globally, public health campaigns to encourage vaccination and increase knowledge of the advantages of H1N1 vaccinations are being launched by governments and health authorities more often, which is driving the market's expansion. To provide universal protection against the virus, these activities center on public education, debunking myths, and promoting proactive immunization. Improved community immunity and increased vaccination rates are two benefits of these efforts. Governments around the world are also working to upgrade public health facilities so that even the most distant areas and marginalized groups may use them. This is helping to increase vaccination uptake.

Government efforts to combat the H1N1 pandemic, both domestically and globally, would be advantageous to the market's expansion. Health organizations like the World Health Organisation (WHO) have played a crucial role in the development of vaccinations and in facilitating their effective dissemination. Following the 2009 H1N1 influenza pandemic, the US government launched a US$ 3 billion H1N1 vaccine project, hiring five significant corporations to create an H1N1 vaccine.

The National Influenza Centres and WHO Collaborating Centres are in charge of continuously monitoring the influenza viruses that are circulating in humans as part of the WHO's Global Influenza Surveillance and Response System. The composition of influenza vaccines is updated twice a year.

Key factors hampering the Market growth

Lack of skilled professionals along with low interest in flu Likely to hampe...

Background # Seasonal influenza virus is a common cause of acute lower respiratory infection (ALRI) in young children. In 2008, we estimated that 20 million influenza-virus-associated ALRI and 1 million influenza-virus-associated severe ALRI occurred in children under 5 years globally. Despite this substantial burden, only a few low-income and middle-income countries have adopted routine influenza vaccination policies for children and, where present, these have achieved only low or unknown levels of vaccine uptake. Moreover, the influenza burden might have changed due to the emergence and circulation of influenza A/H1N1pdm09. We aimed to incorporate new data to update estimates of the global number of cases, hospital admissions, and mortality from influenza-virus-associated respiratory infections in children under 5 years in 2018. # Methods # We estimated the regional and global burden of influenza-associated respiratory infections in children under 5 years from a systematic review of 100 studies published between Jan 1, 1995, and Dec 31, 2018, and a further 57 high-quality unpublished studies. We adapted the Newcastle-Ottawa Scale to assess the risk of bias. We estimated incidence and hospitalisation rates of influenza-virus-associated respiratory infections by severity, case ascertainment, region, and age. We estimated in-hospital deaths from influenza virus ALRI by combining hospital admissions and in-hospital case-fatality ratios of influenza virus ALRI. We estimated the upper bound of influenza virus-associated ALRI deaths based on the number of in-hospital deaths, US paediatric influenza-associated death data, and population-based childhood all-cause pneumonia mortality data in six sites in low-income and lower-middle-income countries. # Findings # In 2018, among children under 5 years globally, there were an estimated 109*5 million influenza virus episodes (uncertainty range [UR] 63*1-190*6), 10*1 million influenza-virus-associated ALRI cases (6*8-15*1); 870 000 influenza-virus-associated ALRI hospital admissions (543 000-1 415 000), 15 300 in-hospital deaths (5800-43 800), and up to 34 800 (13 200-97 200) overall influenza-virus-associated ALRI deaths. Influenza virus accounted for 7% of ALRI cases, 5% of ALRI hospital admissions, and 4% of ALRI deaths in children under 5 years. About 23% of the hospital admissions and 36% of the in-hospital deaths were in infants under 6 months. About 82% of the in-hospital deaths occurred in low-income and lower-middle-income countries. # Interpretation # A large proportion of the influenza-associated burden occurs among young infants and in low-income and lower middle-income countries. Our findings provide new and important evidence for maternal and paediatric influenza immunisation, and should inform future immunisation policy particularly in low-income and middle-income countries.

Quadrivalent Flu Vaccine Market Outlook

The global Quadrivalent Flu Vaccine market size was estimated to be approximately USD 4.5 billion in 2023, and it is anticipated to grow to around USD 9.8 billion by 2032, demonstrating a compound annual growth rate (CAGR) of 9.2% over the forecast period. The growth of this market is primarily driven by increasing awareness about influenza prevention, favorable government initiatives, and advancements in vaccine development technologies.

One of the critical growth factors in the Quadrivalent Flu Vaccine market is the rising awareness and education about the benefits of vaccination in preventing influenza. Governments and health organizations worldwide have been ramping up efforts to educate the public about the importance of flu vaccination, aiming to reduce the incidence of influenza-related complications and fatalities. Campaigns and programs run by entities such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have significantly contributed to the increased uptake of flu vaccines.

Another key driver for market growth is the increased focus on vulnerable populations, including pediatric, geriatric, and immunocompromised individuals. These groups are at a higher risk of complications from influenza, making it crucial to ensure high vaccination rates among them. The development of quadrivalent vaccines, which protect against four different flu viruses, has been a significant advancement in this regard, offering broader protection compared to traditional trivalent vaccines.

Technological advancements in vaccine production and distribution have also played a pivotal role in the growth of the Quadrivalent Flu Vaccine market. Innovations such as cell-based and recombinant DNA technologies have enhanced the efficiency and effectiveness of flu vaccines, reducing production times and improving the immune response. Additionally, advancements in cold chain logistics have improved vaccine distribution, ensuring that vaccines remain effective from production to administration.

The role of Seasonal Influenza Vaccines Therapeutics in the broader context of flu prevention cannot be overstated. These therapeutics are essential in managing seasonal outbreaks, providing targeted protection against the most prevalent strains of the virus each year. As the flu virus evolves, so does the formulation of these vaccines, ensuring that they remain effective against new and emerging strains. The development and distribution of seasonal influenza vaccines are supported by extensive research and collaboration among global health organizations, pharmaceutical companies, and governments. This collaborative effort is crucial in maintaining public health and reducing the burden of influenza-related illnesses and deaths worldwide. The ongoing innovation in vaccine therapeutics also opens up new possibilities for more effective and longer-lasting protection, which is vital in the fight against seasonal flu.

On the regional front, North America has been a leading market due to high awareness levels, strong healthcare infrastructure, and supportive government policies. Europe follows closely, benefiting from extensive public health campaigns and robust healthcare systems. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare expenditure, rising awareness, and expanding vaccination programs in countries like China and India.

Vaccine Type Analysis

The Quadrivalent Flu Vaccine market is segmented by vaccine type into Inactivated and Live Attenuated vaccines. Inactivated vaccines, which use killed virus particles to stimulate the immune response, dominate this segment due to their safety profile and effectiveness. These vaccines are particularly suitable for individuals with weakened immune systems, including the elderly and those with chronic health conditions. The stability and ease of storage of inactivated vaccines also make them a preferred choice in various healthcare settings.

Live Attenuated vaccines, on the other hand, contain weakened live viruses that replicate in the body to elicit an immune response without causing the disease. These vaccines are typically administered as nasal sprays and are known for their ability to induce a strong and long-lasting immune response. They are often recommended for healthy individuals aged between 2 and 49 ye